GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2008

Daiichi Sankyo Intends to Purchase U3 Pharma for Roughly $236M

  • Daiichi Sankyo is taking over U3 Pharma for €150 million, or about $236.22 million. U3 Pharma is a preclinical-stage German company focusing on antibody-based cancer drugs.

    U3 Pharma's lead product, which is being codeveloped with Amgen, is U3-1287 (AMG 888). The compound is designed as a fully human anti-HER3 mAb to inhibit oncogenic signaling and tumor proliferation. The companies intend to initiate clinical development this year.

    This transaction will feed Daiichi Sankyo’s clinical pipeline of anticancer agents. The company has multiple candidates in Phase III programs. Daiichi also owns rights to commercialize Amgen’s late-stage compound denosumab in Japan.

    “Our acquisition of U3 Pharma is an ideal strategic fit for our oncology portfolio,” remarks Takashi Shoda, president and CEO of Daiichi Sankyo. “We currently have three human monoclonal antibodies in development. Additionally, in March 2008, we announced that we were expanding our joint research venture with another German company MorphoSys for its advanced human combinatorial antibody library and its phage-display technologies. One of our goals for Daiichi Sankyo is to increase our presence in novel therapeutics in the oncology arena.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?